SCHEMBL16253000

SCHEMBL16253000

CC(C)(C)C1CCCCN1c1ncc(C(F)(F)F)cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.50
CNR1 P21554 1/20 0.50
POLB P06746 2/20 0.49
SMN1; SMN2 Q16637 7/20 0.47
LMNA P02545 3/20 0.47
ALDH1A1 P00352 4/20 0.44
HTT P42858 2/20 0.44
MAPT P10636 5/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
HPGD P15428 2/20 0.43
CYP2C9 P11712 3/20 0.43
CYP2C19 P33261 3/20 0.43
GAA P10253 2/20 0.43
KDM4E B2RXH2 2/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
NPSR1 Q6W5P4 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9891841 0.96 CNR2 (0.53) CNR2CNR1POLBSMN1; SMN2LMNA
SCHEMBL9891496 0.91 POLB (0.52) CNR2CNR1POLBSMN1; SMN2LMNA
SCHEMBL16254976 0.85 POLB (0.51) CNR2CNR1POLBSMN1; SMN2LMNA
SCHEMBL16253034 0.82 SMN1; SMN2 (0.49) CNR2CNR1POLBSMN1; SMN2LMNA
SCHEMBL16480423 0.81 CNR1 (0.53) CNR2CNR1POLBSMN1; SMN2LMNA
SCHEMBL9891889 0.80 ALDH1A1 (0.44) CNR2CNR1POLBSMN1; SMN2LMNA
SCHEMBL14724229 0.79 POLB (0.48) CNR2CNR1POLBSMN1; SMN2LMNA
SCHEMBL3783905 0.78 CNR1 (0.58) CNR2CNR1POLBSMN1; SMN2LMNA
SCHEMBL9892995 0.78 CNR1 (0.50) CNR2CNR1POLBSMN1; SMN2LMNA
SCHEMBL13257030 0.77 CNR1 (0.57) CNR2CNR1POLBSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8889670-B2 Heterocyclic compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-18 US disclosed
US-20110312944-A1 Heterocyclic Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312944-A1 Heterocyclic Compounds Which Modulate The CB2 Receptor CNR2, CNR1, OPRL1 CNR2 1/4885CNR1 2/4885POLB 4666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.